Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed Drugs

2002/01/01 by Kelly M. Mahar Doan, Joan E. Humphreys, Lindsey O. Webster +6 · 29 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Drug Transport and Resistance Mechanisms #Protein Interaction Studies and Fluorescence Analysis #Epilepsy research and treatment

paper · doi:10.1124/jpet.102.039255

Cited by

• Balanced Permeability Index: A Multiparameter Index for Improved In Vitro Permeability
• Convection-enhanced delivery for treatment of brain tumors
• The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses
• Lead- and drug-like compounds: the rule-of-five revolution
• Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling. [europepmc]
• Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery. [europepmc]
• Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. [europepmc]
• New predictive models for blood-brain barrier permeability of drug-like molecules. [europepmc]
• Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation. [europepmc]
• Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. [europepmc]
• Targeting protein kinases in central nervous system disorders. [europepmc]
• Physicochemical selectivity of the BBB microenvironment governing passive diffusion--matching with a porcine brain lipid extract artificial membrane permeability model. [europepmc]
• A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. [europepmc]
• The role of shear stress in Blood-Brain Barrier endothelial physiology. [europepmc]
• Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. [europepmc]
• Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. [europepmc]
• Improving the prediction of the brain disposition for orally administered drugs using BDDCS. [europepmc]
• Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. [europepmc]
• Urea-based inhibitors of Trypanosoma brucei methionyl-tRNA synthetase: selectivity and in vivo characterization. [europepmc]
• Computational prediction of blood-brain barrier permeability using decision tree induction. [europepmc]
• Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor that Affords Robust CNS Aβ Reduction. [europepmc]
• Prediction of drug-ABC-transporter interaction--Recent advances and future challenges. [europepmc]
• Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. [europepmc]
• Computational analysis of calculated physicochemical and ADMET properties of protein-protein interaction inhibitors. [europepmc]
• Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain. [europepmc]
• Predicting apparent passive permeability of Caco-2 and MDCK cell-monolayers: A mechanistic model. [europepmc]
• Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial. [europepmc]
• Lasmiditan mechanism of action - review of a selective 5-HT 1F agonist. [europepmc]
• WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma. [europepmc]